| 摘要 |
Compounds having the following formula (E): Formula E or a pharmaceutically acceptable salt thereof, wherein R, R′, R″, X and n are as defined herein are provided. Methods comprising use of such compounds for the treatment of neurologic disorders, such as pantothenate kinase-associated neurodegeneration, and pharmaceutical compositions containing such compounds, and their use in treatment of neurologic disorders are also provided.; |
| 主权项 |
1. A compound having the formula:or a pharmaceutically acceptable salt thereof, wherein
R is an amino acid side chain; each occurrence of X is, independently, halogen, alkyl, alkenyl, halogenated alkyl, —CN, —NO2, —C(O)2R1, —C(O)R1, or —OR2; n is 1, 2, 3, 4 or 5; each occurrence of R1 is independently C1-6 alkyl; each occurrence of R2 is independently C1-6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, aryl or polyethylene glycol (PEG), each of which is optionally substituted by one or more halogen; R′ is C1-C20 alkyl, C2-C20 alkenyl, alkynyl, cycloalkyl, cycloalkenyl, cycloalkylalkyl, cycloalkenylalkyl, aryl, arylalkyl, heterocyclyl, heteroaryl, heterocyclylalkyl, or heteroarylalkyl, each of which is optionally substituted by one or more halogen; and R″ is substituted or unsubstituted C1-C20 alkyl, substituted or unsubstituted C2-C20 alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted cycloalkylalkyl, substituted or unsubstituted cycloalkenylalkyl, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocyclylalkyl, substituted or unsubstituted heteroarylalkyl or PEG, each of which is optionally substituted by one or more halogen. |
